Alumis said its TYK2 inhibitor failed to meet efficacy goals in a mid-stage lupus study, adding to a growing set of setbacks for TYK2 blockers in autoimmune indications outside psoriasis and psoriatic arthritis. The company characterized the program as having a “clear path forward,” but the Phase 2 outcome removes a near-term proof point. The news confirms continued difficulty translating TYK2 biology into consistent lupus performance, a challenge for investors and partners assessing future dosing, responder subgroups, and endpoint strategy. The follow-on decision-making will likely hinge on whether Alumis can identify prespecified or emerging subpopulations for a Phase 3 transition. Separately, reporting indicates the program will move toward Phase 3 development for the TYK2 inhibitor, suggesting the company is leaning on evidence from subgroup analyses while reevaluating what the failed trial means for overall registrational potential. For the field, the readout reinforces how brittle late-to-mid translational risk remains in systemic autoimmune development and why endpoint strategy and safety/tolerability data will dominate the next milestone discussions.